CLC number:
On-line Access: 2024-08-27
Received: 2023-10-17
Revision Accepted: 2024-05-08
Crosschecked: 0000-00-00
Cited: 0
Clicked: 4660
Yi ZHAO, Benzheng ZHANG, Qianqian ZHANG, Xiaowei MA, Helin FENG. Tumor-associated macrophages in osteosarcoma[J]. Journal of Zhejiang University Science B, 2021, 22(11): 885-892.
@article{title="Tumor-associated macrophages in osteosarcoma",
author="Yi ZHAO, Benzheng ZHANG, Qianqian ZHANG, Xiaowei MA, Helin FENG",
journal="Journal of Zhejiang University Science B",
volume="22",
number="11",
pages="885-892",
year="2021",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B2100029"
}
%0 Journal Article
%T Tumor-associated macrophages in osteosarcoma
%A Yi ZHAO
%A Benzheng ZHANG
%A Qianqian ZHANG
%A Xiaowei MA
%A Helin FENG
%J Journal of Zhejiang University SCIENCE B
%V 22
%N 11
%P 885-892
%@ 1673-1581
%D 2021
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B2100029
TY - JOUR
T1 - Tumor-associated macrophages in osteosarcoma
A1 - Yi ZHAO
A1 - Benzheng ZHANG
A1 - Qianqian ZHANG
A1 - Xiaowei MA
A1 - Helin FENG
J0 - Journal of Zhejiang University Science B
VL - 22
IS - 11
SP - 885
EP - 892
%@ 1673-1581
Y1 - 2021
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B2100029
Abstract: osteosarcoma (OS) is the most common primary bone tumor in children and adolescents. It is an aggressive tumor with a tendency to spread to the lung, which is the most common site of metastasis. Patients with advanced OS with metastases have poor prognoses despite the application of chemotherapy, thus highlighting the need for novel therapeutic targets. The tumor microenvironment (TME) of OS is confirmed to be essential for and supportive of tumor growth and dissemination. The immune component of the OS microenvironment is mainly composed of tumor-associated macrophages (TAMs). In OS, TAMs promote tumor growth and angiogenesis and upregulate the cancer stem cell-like phenotype. However, TAMs inhibit the metastasis of OS. Therefore, much attention has been paid to investigating the mechanism of TAMs in OS development and the progression of immunotherapy for OS. In this article, we aim to summarize the roles of TAMs in OS and the major findings on the application of TAMs in OS treatment.
[1]AlfrancaA, Martinez-CruzadoL, TorninJ, et al., 2015. Bone microenvironment signals in osteosarcoma development. Cell Mol Life Sci, 72(16):3097-3113.
[2]BalanisN, CarlinCR, 2017. Stress-induced EGF receptor signaling through STAT3 and tumor progression in triple-negative breast cancer. Mol Cell Endocrinol, 451:24-30.
[3]Bighetti-TrevisanRL, SousaLO, CastilhoRM, et al., 2019. Cancer stem cells: powerful targets to improve current anticancer therapeutics. Stem Cells Int, 2019:9618065.
[4]BingleL, BrownNJ, LewisCE, 2002. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol, 196(3):254-265.
[5]Binnemars-PostmaK, BansalR, StormG, et al., 2018. Targeting the Stat6 pathway in tumor-associated macrophages reduces tumor growth and metastatic niche formation in breast cancer. FASEB J, 32(2):969-978.
[6]BrownHK, Tellez-GabrielM, HeymannD, 2017. Cancer stem cells in osteosarcoma. Cancer Lett, 386:189-195.
[7]BuddinghEP, KuijjerML, DuimRAJ, et al., 2011. Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents. Clin Cancer Res, 17(8):2110-2119.
[8]ChengDD, LiSJ, ZhuB, et al., 2018. EEF1D overexpression promotes osteosarcoma cell proliferation by facilitating Akt-mTOR and Akt-Bad signaling. J Exp Clin Cancer Res, 37:50.
[9]CorreI, VerrecchiaF, CrennV, et al., 2020. The osteosarcoma microenvironment: a complex but targetable ecosystem. Cells, 9(4):976.
[10]DanieauG, MoriceS, RédiniF, et al., 2019. New insights about the Wnt/β-catenin signaling pathway in primary bone tumors and their microenvironment: a promising target to develop therapeutic strategies? Int J Mol Sci, 20(15):3751.
[11]DumarsC, NgyuenJM, GaultierA, et al., 2016. Dysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma. Oncotarget, 7(48):78343-78354.
[12]FanQM, JingYY, YuGF, et al., 2014. Tumor-associated macrophages promote cancer stem cell-like properties via transforming growth factor-beta1-induced epithelial-mesenchymal transition in hepatocellular carcinoma. Cancer Lett, 352(2):160-168.
[13]GenselJC, ZhangB, 2015. Macrophage activation and its role in repair and pathology after spinal cord injury. Brain Res, 1619:1-11.
[14]GibbsCP, KukekovVG, ReithJD, et al., 2005. Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia, 7(11):967-976.
[15]HanQL, ShiHG, LiuF, 2016. CD163+ M2-type tumor-associated macrophage support the suppression of tumor-infiltrating T cells in osteosarcoma. Int Immunopharmacol, 34:101-106.
[16]HanY, GuoW, RenTT, et al., 2019. Tumor-associated macrophages promote lung metastasis and induce epithelial-mesenchymal transition in osteosarcoma by activating the COX-2/STAT3 axis. Cancer Lett, 440-441:116-125.
[17]HeR, WuJX, ZhangY, et al., 2018. LncRNA LINC00628 overexpression inhibits the growth and invasion through regulating PI3K/Akt signaling pathway in osteosarcoma. Eur Rev Med Pharmacol Sci, 22(18):5857-5866.
[18]HegabAE, OzakiM, KameyamaN, et al., 2019. Effect of FGF/FGFR pathway blocking on lung adenocarcinoma and its cancer-associated fibroblasts. J Pathol, 249(2):193-205.
[19]HeymannMF, LézotF, HeymannD, 2019. The contribution of immune infiltrates and the local microenvironment in the pathogenesis of osteosarcoma. Cell Immunol, 343:103711.
[20]HuHL, BaiHS, PanHX, 2015. Correlation between TAMs and proliferation and invasion of type I endometrial carcinoma. Asian Pac J Trop Med, 8(8):643-650.
[21]InagakiY, HookwayE, WilliamsKA, et al., 2016. Dendritic and mast cell involvement in the inflammatory response to primary malignant bone tumours. Clin Sarcoma Res, 6:13.
[22]JayasingamSD, CitartanM, TangTH, et al., 2020. Evaluating the polarization of tumor-associated macrophages into M1 and M2 phenotypes in human cancer tissue: technicalities and challenges in routine clinical practice. Front Oncol, 9:1512.
[23]JoyceJA, PollardJW, 2009. Microenvironmental regulation of metastasis. Nature Rev Cancer, 9(4):239-352.
[24]KimuraY, SumiyoshiM, 2015. Antitumor and antimetastatic actions of dihydroxycoumarins (esculetin or fraxetin) through the inhibition of M2 macrophage differentiation in tumor-associated macrophages and/or G1 arrest in tumor cells. Eur J Pharmacol, 746:115-125.
[25]KimuraY, SumiyoshiM, 2016. Resveratrol prevents tumor growth and metastasis by inhibiting lymphangiogenesis and M2 macrophage activation and differentiation in tumor-associated macrophages. Nutr Cancer, 68(4):667-678.
[26]KimuraY, SumiyoshiM, BabaK, 2016. Antitumor and antimetastatic activity of synthetic hydroxystilbenes through inhibition of lymphangiogenesis and M2 macrophage differentiation of tumor-associated macrophages. Anticancer Res, 36(1):137-148.
[27]KlämbtC, 2000. EGF receptor signalling: the importance of presentation. Curr Biol, 10(10):R388-R391.
[28]LeeCH, LiuSY, ChouKC, et al., 2014. Tumor-associated macrophages promote oral cancer progression through activation of the Axl signaling pathway. Ann Surg Oncol, 21(3):1031-1037.
[29]LewisCE, HughesR, 2007. Inflammation and breast cancer. Microenvironmental factors regulating macrophage function in breast tumours: hypoxia and angiopoietin-2. Breast Cancer Res, 9(3):209.
[30]LiYS, LiuQ, TianJ, et al., 2019. Angiogenesis process in osteosarcoma: an updated perspective of pathophysiology and therapeutics. Am J Med Sci, 357(4):280-288.
[31]LimB, WoodwardWA, WangXP, et al., 2018. Inflammatory breast cancer biology: the tumour microenvironment is key. Nat Rev Cancer, 18(8):485-499.
[32]LinXR, ChenLJ, YaoYD, et al., 2015. CCL18-mediated down-regulation of miR98 and miR27b promotes breast cancer metastasis. Oncotarget, 6(24):20485-20499.
[33]LiuF, SunJ, YuW, et al., 2020. Quantum dot-pulsed dendritic cell vaccines plus macrophage polarization for amplified cancer immunotherapy. Biomaterials, 242:119928.
[34]Lopez-YrigoyenM, CassettaL, PollardJW, 2020. Macrophage targeting in cancer. Ann N Y Acad Sci, 242:119928.
[35]MantovaniA, MarchesiF, MalesciA, et al., 2017. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol, 14(7):399-416.
[36]MurdochC, MuthanaM, CoffeltSB, et al., 2008. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer, 8(8):618-631.
[37]NgambenjawongC, GustafsonHH, PunSH, 2017. Progress in tumor-associated macrophage (TAM)-targeted therapeutics. Adv Drug Deliv Rev, 114:206-221.
[38]OsinskyS, BubnovskayaL, GanusevichI, et al., 2011. Hypoxia, tumour-associated macrophages, microvessel density, VEGF and matrix metalloproteinases in human gastric cancer: interaction and impact on survival. Clin Transl Oncol, 13(2):133-138.
[39]PahlJHW, KwappenbergKMC, VarypatakiEM, et al., 2014. Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-γ. J Exp Clin Cancer Res, 33:27.
[40]PerryCJ, Muñoz-RojasAR, MeethKM, et al., 2018. Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity. J Exp Med, 215(3):877-893.
[41]PetersonTE, KirkpatrickND, HuangYH, et al., 2016. Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. Proc Natl Acad Sci USA, 113(16): 4470-4475.
[42]PunzoF, BelliniG, TortoraC, et al., 2020. Mifamurtide and TAM-like macrophages: effect on proliferation, migration and differentiation of osteosarcoma cells. Oncotarget, 11(7):687-698.
[43]RahmaOE, HodiFS, 2019. The intersection between tumor angiogenesis and immune suppression. Clin Cancer Res, 25(18):5449-5457.
[44]SégalinyAI, MohamadiA, DizierB, et al., 2015. Interleukin-34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment. Int J Cancer, 137(1):73-85.
[45]ShaoXJ, XiangSF, ChenYQ, et al., 2019. Inhibition of M2-like macrophages by all-trans retinoic acid prevents cancer initiation and stemness in osteosarcoma cells. Acta Pharmacol Sin, 40(10):1343-1350.
[46]TalukdarS, EmdadL, DasSK, et al., 2016. Evolving strategies for therapeutically targeting cancer stem cells. Adv Cancer Res, 131:159-191.
[47]TiainenS, MasarwahA, OikariS, et al., 2020. Tumor microenvironment and breast cancer survival: combined effects of breast fat, M2 macrophages and hyaluronan create a dismal prognosis. Breast Cancer Res Treat, 179(3):565-575.
[48]TianZQ, HouXJ, LiuWT, et al., 2019. Macrophages and hepatocellular carcinoma. Cell Biosci, 9:79.
[49]UeharaT, EikawaS, NishidaM, et al., 2019. Metformin induces CD11b+-cell-mediated growth inhibition of an osteosarcoma: implications for metabolic reprogramming of myeloid cells and anti-tumor effects. Int Immunol, 31(4):187-198.
[50]WanSS, ZhaoED, KryczekI, et al., 2014. Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells. Gastroenterology, 147(6):1393-1404.
[51]WernoC, MenradH, WeigertA, et al., 2010. Knockout of HIF-1α in tumor-associated macrophages enhances M2 polarization and attenuates their pro-angiogenic responses. Carcinogenesis, 31(10):1863-1872.
[52]WhelanJS, DavisLE, 2018. Osteosarcoma, chondrosarcoma, and chordoma. J Clin Oncol, 36(2):188-193.
[53]WuH, XuJB, HeYL, et al., 2012. Tumor-associated macrophages promote angiogenesis and lymphangiogenesis of gastric cancer. J Surg Oncol, 106(4):462-468.
[54]XiaoQ, ZhangXP, WuYY, et al., 2014. Inhibition of macrophage polarization prohibits growth of human osteosarcoma. Tumour Biol, 35(8):7611-7616.
[55]XuanWJ, QuQ, ZhengB, et al., 2015. The chemotaxis of M1 and M2 macrophages is regulated by different chemokines. J Leukocyte Biol, 97(1):61-69.
[56]YanGN, LvYF, GuoQN, 2016. Advances in osteosarcoma stem cell research and opportunities for novel therapeutic targets. Cancer Lett, 370(2):268-274.
[57]YangCX, HeLY, HePQ, et al., 2015. Increased drug resistance in breast cancer by tumor-associated macrophages through IL-10/STAT3/bcl-2 signaling pathway. Med Oncol, 32(2):14.
[58]YangD, LiuKY, FanL, et al., 2020. LncRNA RP11-361F15.2 promotes osteosarcoma tumorigenesis by inhibiting M2-like polarization of tumor-associated macrophages of CPEB4. Cancer Lett, 473:33-49.
[59]YinSC, HuangJY, LiZ, et al., 2017. The prognostic and clinicopathological significance of tumor-associated macrophages in patients with gastric cancer: a meta-analysis. PLoS ONE, 12(1):e0170042.
[60]ZhangQW, LiuL, GongCY, et al., 2012. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS ONE, 7(12):e50946.
[61]ZhaoXX, QuJK, SunYC, et al., 2017. Prognostic significance of tumor-associated macrophages in breast cancer: a meta-analysis of the literature. Oncotarget, 8(18):30576-30586.
[62]ZhouQ, XianM, XiangSF, et al., 2017. All-trans retinoic acid prevents osteosarcoma metastasis by inhibiting M2 polarization of tumor-associated macrophages. Cancer Immunol Res, 5(7):547-559.
Open peer comments: Debate/Discuss/Question/Opinion
<1>